← Leaderboards
Christopher Lucas Prince
Verra Therapeutics, Inc.
$2,390,996
Attributed
$2,390,996
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,390,996 · 2
By mechanism
R44$1,999,973 · 1
R43$391,023 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Macrophage”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Frederic Geissmann · Sloan-Kettering Inst Can Research$12,957,901
- Adam David Hoppe · South Dakota State University$9,046,059
- Niccolo Terrando · Duke University$6,839,733
- Markus Bosmann · Boston University Medical Campus$6,657,387
- Benson Edagwa · University Of Nebraska Medical Center$6,144,379
Research focus
MacrophageProteinsDoseLungMucous Body SubstancePharmaceutical PreparationsDesmosineDisease PhenotypeImmunogenicityIn VivoMetalloproteasesMouse ModelPenetrationPeptide HydrolasesCellsCigarette Smoke-Induced CopdBiological MarkersDisease ModelBronchoalveolar LavageEpithelial CellsCause Of DeathInflammatoryMaximum Tolerated DoseSeverity Of Illness
Grant awards (3)
A Disease-Modifying Protein Therapeutic for the Treatment of COPD$635,475
R44 · FY2024 · HL · contact PI
A Disease-Modifying Protein Therapeutic for the Treatment of COPD$1,364,498
R44 · FY2023 · HL · contact PI
A Disease-Modifying Protein Therapeutic for the Treatment of COPD$391,023
R43 · FY2019 · HL · contact PI